Arena's S1PR1 agonist meets in Phase II for UC

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS trial to treat ulcerative colitis. The company, which announced the news after market hours on Monday, was up $7.61 (25%) to $38.50 in after-hours trading.

Arena plans to start a Phase III program for the sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist to treat UC, but the company said it is too early to comment on a timeline for when the program is slated to start...